Arcus Biosciences Inc RCUS

$18.54 -0.82 (-4.24%)

Valuation

Market cap
2,465,167,000
Revenue TTM
$247,000,000
Net income TTM
$-353,000,000
PE ratio
0.00
Forward PE
—
Profit margin
-142.92%
Debt to equity
0.22

Trading

Volume
5,925,200
Avg volume
1,900,284
Day's range
$18.43 – $19.09
Shares out
127,333,000
Stochastic %K
15%
Beta
0.94
Analysts
Strong Sell
Price target
$39.85

Price

Company profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody....

Show more

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Industry
Biotechnology
Sector
Healthcare
Phone
510 694 6200
Website
https://arcusbio.com
Address
3928 Point Eden Way, Hayward, United States

Latest news

Stocktwits

stcks Oct 23, 5:40 PM
$RCUS $TGTX $AUPH https://x.com/atbarnhill/status/2113451720357384304?s=46&t=ox6WFr0tB-AKDDHQmadpHA
0 replies
stcks Oct 22, 6:51 PM 0 replies
OpenOutcrier Oct 22, 1:06 PM
$RCUS (-9.8% pre) Arcus Biosciences prices $250M common stock offering https://ooc.bz/l/118188
0 replies
stcks Oct 22, 4:10 AM
$RCUS Catalyst going forward!
0 replies
stcks Oct 22, 4:08 AM
$RCUS analyst targets pre-offering
0 replies
stcks Oct 22, 3:53 AM
$RCUS a wasted year!
1 replies
stcks Oct 22, 3:13 AM
$RCUS The deal: 14,285,715 shares at $17.50, for $250.0M gross. That's the bottom of the range. Here's what it works out to, using the 127.0M shares outstanding: New shares: The deal: 14,285,715 shares at $17.50, for $250.0M gross., or 11.2% more shares. Cash: about $944M after fees, up from $694M. Underwriters' option: they can buy up to 2,142,857 more shares within 30 days. Or 12.9% more shares Closing: expected Oct 23. Discount: 8.4% below today's $19.10 That's a bit deeper than the 6.4% median in the deals like this. Pricing at the low end hints that buyers had the leverage on this deal, and $17.50 is right at the 52-week low of $17.45.
1 replies
stcks Oct 22, 2:55 AM
$RCUS almost exactly a year ago, on Oct 30, 2025, Arcus sold $250M of stock at $18.25. 🤮
0 replies